Early vascular aging (EVA): consequences and prevention

Vascular Health and Risk Management

Volumn 4, Issue 3, 2008, Pages 547-552

  Nilsson, Peter M ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Aging; Cardiovascular; Diabetes; Hypertension; Risk factor; Smoking; Vascular

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METOPROLOL; PRAVASTATIN; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SULFONYLUREA; TELMISARTAN; TELOMERASE; VARENICLINE;

AGING; ALCOHOL CONSUMPTION; ANKLE BRACHIAL INDEX; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MOLECULAR MECHANICS; NONHUMAN; PATIENT EDUCATION; POPULATION RESEARCH; PREVALENCE; PRIMARY PREVENTION; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; SWEDEN; TELOMERE; TOBACCO DEPENDENCE;

BLOOD VESSELS; DIABETES MELLITUS, TYPE 2; ELASTICITY; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; SMOKING; TELOMERE;

EID: 47949129941     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, et al. 2007. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis, 195:83-9.
2. Adams JM, White M. 2004. Biological ageing. A fundamental, biological link between socio-economic status and health? Eur J Pub Health, 14:331-4.
3. Andresdottir MB, Sigurdsson G, Sigvaldason H, et al. 2002. Reykjavik Cohort Study. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J, 23:1655-63.
4. Artandi SE. 2006. Telomeres, telomerase, and human disease. N Engl J Med, 355:1195-7.
5. Aviv A. 2002. Telomeres, sex, reactive oxygen species, and human cardiovascular aging. J Mol Med, 80:689-95.
6. Aviv A, Levy D, Mangel M. 2003. Growth, telomere dynamics and successful and unsuccessful human aging. Mech Ageing Dev, 124:829-37.
7. Bain SC, Gill GV, Dyer PH, et al. 2003. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med, 20:808-11.
8. Bairey Merz CN, Dwyer J, Nordstrom CK, et al. 2002. Psychosocial stress and cardiovascular disease: pathophysiological links. Behav Med, 27:141-7.
9. Benetos A, Gardner JP, Zureik M, et al. 2004. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension, 43:182-5.
10. Bots ML, Grobbee DE. 2002. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther, 16:341-51.
11. Brouilette S, Singh RK, Thompson JR, et al. 2003. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol, 23:842-6.
12. Brouilette SW, Moore JS, McMahon AD, et al. 2007. West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet, 369:107-14.
13. Cawthon RM, Smith KR, O'Brien E, et al. 2003. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet, 361:393-5.
14. Chandola T, Brunner E, Marmot M. 2006. Chronic stress at work and the metabolic syndrome: prospective study. BMJ, 332:521-5.
15. Cherkas LF, Aviv A, Valdes AM, et al. 2006. The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell, 5:61-5.
16. [CTT] Cholesterol Treatment Trialists' Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet, 366:1267-78.
17. [CRESCENDO] Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes; Sanofi-Aventis. 2005. Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO) [online]. Accessed on October 10, 2007. URL: http://clinicaltrials.gov/ ct/show/NCT00263042?order=1.
18. Dagenais GR, Pogue J, Fox K, et al. 2006. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, 368:581-8.
19. Danaei G, Lawes CM, Vander Hoorn S, et al. 2006. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet, 368:1651-9.
20. [DGI] Diabetes Genetics Initiative of Broad Institute of Harvard and IMT, Lund University and NOVARTIS Institutes for Biomedical Research. 2007. Genome-wide association analysis identifies three novel loci for type-2 diabetes and one for triglyceride levels. Science, 316:1331-6.
21. Edward G. Lakatta EG, Najjar SS. 2002. Vascular aging: An emerging new global cardiovascular risk. The Valencia Forum [abstract online]. Accessed on October 10, 2007. URL: http://www.valenciaforum.com/Keynotes/ el.html.
22. Epel ES, Blackburn EH, Lin J, et al. 2004. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA, 101:17312-15.
23. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. 2007. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol, 165:14-21.
24. Fuster JJ, Diez J, Andrès V. 2007. Telomere dysfunction and hypertension. J Hypertens, 25:2185-92.
25. Gardner JP, Li S, Srinivasan SR, et al. 2005. Rise in insulin resistance is associated with escalated telomere attrition. Circulation, 111:2171-7.
26. Graham I, Atar D, Borch-Johnsen K, et al. 2007. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J, 28:2375-414.
27. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 352:1685-95.
28. Hedblad B, Nilsson P, Eriksson K-F, et al. 2000. Risk factor pattern and prevalence of atherosclerotic disease in subjects with the metabolic syndrome. Data from the Malmö Diet and Disease Study. Diabetic Medicine, 17:299-307.
29. Hedblad B, Wikstrand J, Janzon L, et al. 2001. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation, 103:1721-6.
30. Hedblad B, Nilsson PM, Zambamni A, et al. 2007. Rosiglitazone reduces carotid intima-media thickness progression over 1 year in patients with type 2 diabetes but not in non-diabetic people who have insulin resistance alone. J Internal Med, 261:293-305.
31. Home PD, Pocock SJ, Beck-Nielsen H, et al. 2005. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia, 48:1726-35.
32. Hu G, Jousilahti P, Qiao Q, et al. 2005. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia, 48:856-61.
33. Jarvisalo MJ, Juonala M, Raitakari OT. 2006. Assessment of inflammatory markers and endothelial function. Curr Opin Clin Nutr Metab Care, 9:547-52.
34. Jorenby DE, Hays JT, Rigotti NA, et al. 2006. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, 296:56-63.
35. Kaplan GA, Keil JE. 1993. Socio-economic factors and cardiovascular disease: a review of the literature. Circulation, 88:1973-98.
36. Laurent S, Cockkroft J, Van Bortel L, et al. 2006. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J, 27:2588-605.
37. Leeson CP, Hingorani AD, Mullen MJ, et al. 2002. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res, 90:1153-8.
38. Marmot M. 2006. Health in an unequal world. Lancet, 369:2081-94.
39. Najjar SS, Scuteri A, Lakatta EG. 2005. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension, 46:454-62.
40. Nathan DM, Buse JB, Davidson MB, et al. 2006. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29:1963-72.
41. Nilsson P. 1996. Premature ageing - the link between psychosocial risk factors and disease? Med Hypotheses, 47:39-42.
42. Nilsson PM, Nilsson J-Å, Berglund G. 2004, Family burden of cardiovascular mortality - risk implications for offspring in a national register linkage study based upon the Malmö Preventive Project. J Intern Med, 255:229-35.
43. Nilsson PM, Engberg M, Nilsson J-Å, et al. 2005. Adverse social factors predict early ageing in middle-aged men and women: the Ebeltoft Health Study, Denmark. Scand J Public Health, 31:1-6.
44. Nilsson PM, Engström G, Hedblad B, et al. 2006. Plasma adiponectin levels are inversely associated with carotid intima media thickness and markers of insulin resistance in middle-aged men. ATVB, 26:2758-62.
45. Obana N, Takagi S, Kinouchi Y, et al. 2003. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med, 42:150-3.
46. Ogami M, Ikura Y, Ohsawa M, et al. 2004. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol, 24:546-50.
47. Plavinski SL, Plavinskaya SI, Klimov AN. 2003. Social factors and increase in mortality in Russia in the 1990s: prospective cohort study. BMJ, 326:1240-2.
48. Rietzschel ER, De Buyzere ML, Bekaert S, et al. 2007. Asklepios Investigators. Rationale, design, methods and baseline characteristics of the Asklepios Study. Eur J Cardiovasc Prev Rehab, 14: 179-91.
49. Rimm EB, Chan J, Stampfer MJ, et al. 1995. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ, 310-555-9.
50. Rosvall M, Östergren PO, Hedblad B, et al. 2000. Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmo Diet and Cancer Study. Am J Epidemiol, 152:334-46.
51. Rosvall M, Janzon L, Berglund G, et al. 2005a. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis, 179:325-31.
52. Rosvall M, Janzon L, Berglund G, et al. 2005b. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med, 257:430-7.
53. Rosvall M, Östergren PO, Hedblad B, et al. 2006. Socioeconomic differences in the progression of carotid atherosclerosis in middle-aged men and women with subclinical atherosclerosis in Sweden. Soc Sci Med, 62:1785-98.
54. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 28:88-136.
55. Samani NJ, Boultby R, Butler R, et al. 2001. Telomere shortening in atherosclerosis. Lancet, 358:472-3.
56. Shan HY, Bai XJ, Chen XM. 2007. Apoptosis is involved in the senescence of endothelial cells induced by angiotensin II. Cell Biol Int, Sep 19; [Epub ahead of print]
57. Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-44.
58. Sundquist K., Li X. 2006. Differences in maternal and paternal transmission of coronary heart disease. Am J Prev Med, 30:480-6.
59. Taddei S, Virdis A, Mattei P, et al. 1997 Hypertension causes premature aging of endothelial function in humans. Hypertension, 29:736-43.
60. Teo K, Yusuf S, Sleight P, et al. ONTARGET/TRANSCEND Investigators. 2004. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, raimpril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J, 148:52-61.
61. Teo KK, Ounpuu S, Hawken S, et al. INTERHEART Study Investigators. 2006. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet, 368:647-58.
62. Valdes AM, Andrew T, Gardner JP, et al. 2005. Obesity, cigarette smoking, and telomere length in women. Lancet, 366:662-4.